China SXT Pharmaceuticals, Inc.
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: CNExchange: Nasdaq
DilutionScan read 37 of China SXT Pharmaceuticals, Inc.'s SEC filings and found 7 warrant series, 1 convertible, 1 ATM program, 1 equity line, 3 shelf registrations and 6 completed offerings on file for SXTC. The latest dilution event on file is an offering on Oct 9, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
SXTC
Collapsing revenue and massive dilution
Snapshot
China SXT is a tiny micro-cap with a shrinking business. FY 2026 revenue dropped 38% to $1.1M while net losses widened to $6.2M, meaning the company lost over five dollars for every dollar it brought in. Gross margins fell to 17%.
What's Happening Right Now
- : The company closed a $9 million registered direct offering that includes warrants allowing holders to receive shares without cash payment if the price falls, potentially adding 63 million new shares.
- : The company announced a 1-for-80 share consolidation effective August 10, 2026 to maintain its Nasdaq listing.
- : China SXT entered an agreement to sell up to $100 million of its Class A ordinary shares through an at-the-market offering program.